Mirikizumab Improves Quality of Life in Patients With Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study

Category Primary study
JournalAmerican Journal of Gastroenterology
Year 2024
This article has no abstract
Epistemonikos ID: bb96ab9a5f33abebb64d5517aaf227244ecb575a
First added on: Feb 19, 2025